|

Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization

RECRUITINGPhase 4Sponsored by Takeshi Morimoto
Actively Recruiting
PhasePhase 4
SponsorTakeshi Morimoto
Started2022-06-14
Est. completion2030-03
Eligibility
Age20 Years+
Healthy vol.Accepted

Summary

The purpose of this study is to evaluate the efficacy and safety aspirin in patients with chronic coronary syndromes without revascularization.

Eligibility

Age: 20 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with chronic coronary syndromes with ≧50% diameter stenosis in one or more major coronary vessels/major branches on coronary CT or coronary angiography but not eligible for coronary revascularization
* Patients for whom consent can be obtained

Exclusion Criteria:

* Patients with history of acute coronary syndromes (ACS)
* Patients with history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)
* Patients with left main trunk stenosis (≥50%)
* Patients for whom aspirin administration is mandatory
* Patients undergoing antithrombotic therapy other than aspirin
* Patients with atrial fibrillation
* Patients with history of stroke within six months
* Patients scheduled for major surgical procedures that will require aspirin discontinuation
* Patients with contraindication of aspirin
* Patients expected to have a prognosis of 1 year or less due to comorbidities
* Women of child-bearing potential or women who have a positive pregnancy test at enrolment or randomization
* Patients who are judged by attending physicians to be inappropriate to participate in this study

Conditions4

Coronary Artery DiseaseHeart DiseaseIschemic Heart DiseaseStable Angina Pectoris

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.